Sanofi India Limited (SANOFI.NS)
NSE · INR · Healthcare · Drug Manufacturers - General
₹2,973.40 (+4.23%) as of
Key statistics
- Market cap
- 68.48B
- P/E (TTM)
- 21.15
- Forward P/E
- 16.65
- EPS (TTM)
- 140.59
- Dividend yield
- 4.31%
- 52-week range
- 2,758.20 – 4,898.00
- Beta
- 0.16
- Revenue (TTM)
- 18.05B
- Profit margin
- 17.94%
- Analyst target
- ₹4,339.67
- Volume
- 13.59k
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Mumbai, India
- Employees
- 1,097
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.